AQSZF Stock - Aequus Pharmaceuticals Inc.
Unlock GoAI Insights for AQSZF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $584,237 | $254,896 | $1.38M | $2.71M | $2.59M |
| Gross Profit | $332,303 | $143,662 | $1.15M | $2.67M | $2.59M |
| Gross Margin | 56.9% | 56.4% | 83.1% | 98.4% | 100.0% |
| Operating Income | $-2,127,199 | $-2,820,286 | $-2,582,536 | $-1,607,530 | $-779,805 |
| Net Income | $-2,177,662 | $-2,964,722 | $-3,210,044 | $-1,809,592 | $-1,045,360 |
| Net Margin | -372.7% | -1163.1% | -232.7% | -66.7% | -40.3% |
| EPS | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.01 |
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Visit WebsiteEarnings History & Surprises
AQSZFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 19, 2026 | — | — | — | — |
Q4 2025 | Dec 1, 2025 | — | $0.00 | — | — |
Q3 2025 | Aug 27, 2025 | — | $-0.00 | — | — |
Q2 2025 | May 21, 2025 | — | $-0.00 | — | — |
Q2 2025 | Apr 24, 2025 | — | $-0.00 | — | — |
Q4 2024 | Nov 8, 2024 | — | $-0.00 | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 9, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-0.00 | — | — |
Q4 2023 | Nov 29, 2023 | — | $-0.00 | — | — |
Q3 2023 | Aug 30, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 31, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 2, 2023 | — | $-0.01 | — | — |
Q4 2022 | Nov 30, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 29, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 17, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.01 | — | — |
Q4 2021 | Nov 3, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.00 | — | — |
Latest News
Frequently Asked Questions about AQSZF
What is AQSZF's current stock price?
What is the analyst price target for AQSZF?
What sector is Aequus Pharmaceuticals Inc. in?
What is AQSZF's market cap?
Does AQSZF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AQSZF for comparison